Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial
Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial
复制标题
DOI：
10.1016/s0006-3223(02)01411-7
复制
发表时间：
2003-01-15
影响因子：
10.6
通讯作者：
van Meter, S
中科院分区：
文献类型：
--
作者：
Davidson, JRT;Weisler, RH;van Meter, S
背景资料：基于较早的试点研究，以及其作用机制的理论考虑，我们进行了一个安慰剂对照，双盲试验的米氮平在创伤后stress disorder.Methods：29例患者随机接受药物高达45毫克/天或安慰剂双盲2：1的比例为8周，数据可用于分析26。主要结果指标包括创伤后应激障碍短期评定访谈（SPRINT）总体改善项目和总分。次要指标包括Davidson创伤量表、创伤后应激障碍结构化访谈和医院焦虑抑郁量表。不良事件也measured.Results：在短期创伤后应激障碍评定访谈全球改善措施，反应率分别为64.7%和20.0%，米氮平和安慰剂。在创伤后应激障碍短期评定访谈、创伤后应激障碍结构化访谈和医院焦虑抑郁量表焦虑子量表评分中，观察到有利于米氮平的治疗效果。结论：米氮平在创伤后应激障碍和广泛性焦虑症状的某些方面比安慰剂更有效。(C)2003生物精神病学学会。
Background: Based on an earlier pilot study, as well as a theoretical consideration of its mechanism of action, we undertook a placebo-controlled, double-blind trial of mirtazapine in posttraumatic stress disorder.Methods: Twenty-nine patients were randomized to receive drug up to 45 mg/day or placebo double-blind on a 2:1 ratio for 8 weeks, with data being available for analysis in 26. Primary outcome measures comprised the Short Posttraumatic Stress Disorder Rating Interview (SPRINT) Global Improvement item and total score. Secondary measures comprised the Davidson Trauma Scale, Structured Interview for Posttraumatic Stress Disorder and Hospital Anxiety Depression Scale. Adverse events were also measured.Results: On the Short Posttraumatic Stress Disorder Rating Interview Global Improvement measure, rates Of response were 64.7% and 20.0% for mirtazapine and placebo. Treatment effects in favor of mirtazapine were noted on the Short Posttraumatic Stress Disorder Rating Interview global, Structured Interview for Posttraumatic Stress Disorder, and Hospital Anxiety Depression Scale anxiety subscale scores. The drug was well tolerated.Conclusions: Mirtazapine was more effective than placebo on some measures in posttraumatic stress disorder and general anxiety symptoms. (C) 2003 Society of Biological Psychiatry.